BION Net Income From Continuing Ops from 2010 to 2026
| BION Stock | CHF 47.05 0.70 1.51% |
Net Income From Continuing Ops | First Reported 2017-12-31 | Previous Quarter -240.9 M | Current Value -100.2 M | Quarterly Volatility 296.8 M |
Check BB Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BB Biotech's main balance sheet or income statement drivers, such as Interest Expense of 6 M, Selling General Administrative of 25.7 M or Total Revenue of 169.9 M, as well as many indicators such as Price To Sales Ratio of 14.91, Dividend Yield of 0.0337 or PTB Ratio of 0.75. BION financial statements analysis is a perfect complement when working with BB Biotech Valuation or Volatility modules.
BION | Net Income From Continuing Ops |
The evolution of Net Income From Continuing Ops for BB Biotech AG provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how BB Biotech compares to historical norms and industry peers.
Latest BB Biotech's Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of BB Biotech AG over the last few years. It is BB Biotech's Net Income From Continuing Ops historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BB Biotech's overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
BION Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | 472,122,691 | |
| Coefficient Of Variation | 168.01 | |
| Mean Deviation | 683,589,974 | |
| Median | 652,816,000 | |
| Standard Deviation | 793,229,373 | |
| Sample Variance | 629212.8T | |
| Range | 2.3B | |
| R-Value | (0.71) | |
| Mean Square Error | 335670.7T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (111,059,343) | |
| Total Sum of Squares | 10067405.4T |
BION Net Income From Continuing Ops History
About BB Biotech Financial Statements
BB Biotech investors use historical fundamental indicators, such as BB Biotech's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BB Biotech. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 68.3 M | 64.9 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for BION Stock Analysis
When running BB Biotech's price analysis, check to measure BB Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BB Biotech is operating at the current time. Most of BB Biotech's value examination focuses on studying past and present price action to predict the probability of BB Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BB Biotech's price. Additionally, you may evaluate how the addition of BB Biotech to your portfolios can decrease your overall portfolio volatility.